Doug Hampton KRAKÓW, Poland, May 31, 2023 /PRNewswire/ — Selvita S.A. [WSE: SLV], one of the largest contract research organization companies in Europe, has published a financial report for Q1 2023*. The Group is growing despite the demanding market, taking on numerous actions to strengthen sales and optimize the business. In Q1 2023, Selvita Group (excl. Ardigen) generated … Read more
On the occasion of World No Tobacco Day, this May 31, Public Health France publishes the figures for smoking in France. After a drop in consumption between 2016 and 2019, consumption has since stabilized… but at a high level. Today, France still has 12 million daily smokers! Each year, Public Health France estimates the prevalence … Read more
SHANGHAI, May 31, 2023 /PRNewswire/ — Asieris Pharmaceuticals (688176)， a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced the phase I clinical data of ANTICIPATE Study was published for the first time at the 2023 American Society of Clinical Oncology (ASCO) … Read more
SAN FRANCISCO, May 31, 2023 /PRNewswire/ — The global cell culture industry size is poised to rise with mega-trends witnessed in stem cell therapy and regenerative medicine, according to the “Cell Culture Industry Data Book, 2023 – 2030,” published by Grand View Research. Moreover, an infusion of funds into life science, biotechnology and biopharmaceutical research activities … Read more
A Norwegian study assures that physically active people have a higher resistance to pain. The virtues linked to physical activity are numerous: prevention of cardiovascular risks, type 2 diabetes or neurodegenerative diseases such as Parkinson’s. A recent Norwegian study, the results of which were published in the journal PLOS Onesuggests that it may also give … Read more
STOCKHOLM, May 31, 2023 /PRNewswire/ — Medivir AB (publ) (“Medivir”) (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, … Read more
MGC Pharma’s pioneering cannabis-based treatment for refractory epilepsy now available to patients in the United Kingdom LONDON, May 31, 2023 /PRNewswire/ — MGC Pharmaceuticals Ltd. (LSE: MXC), (ASX: MXC), (OTC: MGCLF), a leading European pharmaceutical firm specializing in plant-derived medications, announced today that its ground-breaking Investigational Medicinal Product (IMP), CannEpil®, has been successfully imported and received … Read more
– At week 24, upadacitinib 30 mg given alone or as a combination therapy (ABBV-599 high dose [elsubrutinib 60 mg and upadacitinib 30 mg]) met the primary endpoint of systemic lupus erythematosus (SLE) Responder Index (SRI-4) and steroid dose less than or equal to 10 mg prednisone equivalent once per day in patients with moderately to … Read more
SNIPR001 demonstrates proof of principle in reducing E. coli levels in the human gastrointestinal tract SNIPR001 is a novel CRISPR-Cas therapeutic, selectively targeting antibiotic-resistant E. coli which can cause life-threatening infections in vulnerable hematological cancer patients Future studies needed to evaluate the impact of SNIPR001 on reducing the rate of E. coli infections in high-risk … Read more
TAMPA, Floride, 31 mai 2023 /PRNewswire/ — Le 24 mai 2023, la FDA américaine a accordé une exemption de dispositif expérimental (IDE) pour le ballonnet enduit de sirolimus (SCB) MagicTouch PTA de Concept Medical Inc. dans le cadre du traitement des artères fémorales superficielles (AFS). Il s’agit de la quatrième approbation IDE pour le ballonnet recouvert de sirolimus de la société. … Read more